CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lantheus Holdings Inc   (NASDAQ: LNTH)


Lantheus Holdings Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lantheus Holdings Inc's ROI in the third quarter of 2026?
Lantheus Holdings Inc achieved a return on average invested assets (ROI) of 12.18 % in its third quarter of 2026, this is above LNTH's average return on investment of 11.95%.
Lantheus Holdings Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $2 billion

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 84 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 521 to 532.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 21.21 % 24.72 % 18.24 % 18.97 % 21.88 %
Y / Y Net Income Change TTM 60.96 % 1.59 % 45.14 % 95.77 % 27.91 %
Investment (TTM) in Millions 2,501 2,455 2,013 1,894 1,930
Return On Investment (TTM) 12.18 % 13.28 % 14.55 % 12.51 % 9.17 %
LNTH's Overall Ranking # 532 # 521 # 563 # 819 #
Seq. Investment Change TTM 6.89 % 8.07 % 2.76 % 2.11 % 9.99 %
Seq. Net Income Change TTM -1.96 % -1.34 % 19.47 % 39.29 % -38.13 %
Net Income (TTM) in Millions 270 275 279 234 168

LNTH Company Profile >> Back to LNTH Roi Comparisons >> See Annual LNTH Return On Investment



Return On Investment LNTH's Ranking
Within: No.
Industry # 2
Sector # 85
Overall # 532

Return On Investment Statistics
High Average Low
49 %
11.95 %
-9.18 %
(Dec 31 2017)   (Dec 31 2021)



  News about Lantheus Holdings Inc Return on Investment ROI

Lantheus Celebrates CMS Rule Enhancement for Diagnostic Radiopharmaceuticals Translates to Better Patient Access and Care

November 4, 2024

In a significant move for the healthcare landscape, Lantheus Holdings, Inc. has expressed its commendation for the Centers for Medicare and Medicaid Services (CMS) recent rule concerning the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The announcement, made on November 4, 2024, signals a pivotal recognition of specialized diagnostic radiopharmaceuticals, which are critical in diagnosing and managing various diseases effectively.The final rule aims to improve the payment structure for these specialized products, enabling healthcare facilities to provide better access to essential diagnostic services for patients. By refining the accuracy of payment amounts, this reform promises to enhance the financial viability of institutions utilizing these technologies, ultimately leading to improved patient outcomes. Lantheus, a leader in the field, views this adjustment as a landmark recognition of the importance of diagnostic radiopharmaceuticals, allowing clinicians to better “Find, Fight, and Follow” diseases.





Financial Statements
Lantheus Holdings Inc's III. Quarter Investments $ 2,501 Millions LNTH's Balance sheet
Lantheus Holdings Inc's III. Quarter Income $ 22 Millions Quarterly LNTH's Income Statement
LNTH's Income by Division See LNTH's Income by Division


LNTH Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,894 1,740 1,464 1,074 773
Y / Y Investment Growth 8.86 % 18.86 % 36.35 % 38.83 % -2.03 %
Net Income in Millions 234 312 327 28 -71
Y / Y Net Income Growth -25.25 % -4.35 % 1063.86 % - -
Annual Return On Investment 12.33 % 17.96 % 22.32 % 2.61 % -9.22 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 12.33 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LNTH's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LNTH's Competitors
Subscribers only: Roi for Lantheus Holdings Inc's Suppliers
Subscribers only: Return On Investment for LNTH's Customers

Other Ratios
LNTH's Roa LNTH's Inventory Turnover Ratio LNTH's Growth Rates LNTH's Dividend Statistics
LNTH's Profitability Ratios LNTH's Asset Turnover Ratio LNTH's Dividend Growth
LNTH's Roe LNTH's Valuation Ratios LNTH's Financial Strength Ratios LNTH's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %
3m Company  13.24 %
Beone Medicines Ltd   13.17 %
Regeneron Pharmaceuticals Inc   13.00 %
Abbvie Inc   12.87 %

Date modified: 2026-11-09T06:46:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.